Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Next Previous
Trial Profile

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacutamab (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Anaplastic large cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TELLOMAK
  • Sponsors Innate Pharma

Most Recent Events

  • 23 May 2025 According to Innate Pharma media release, long term follow up data from this trial will be presented at the ASCO Annual Meeting 2025.
  • 23 May 2025 Long term follow up data from this trial presented in the Innate Pharma Media Release
  • 13 May 2025 According to an Innate Pharma Media Release, long-term follow-up for Sezary syndrome and mycosis fungoides will be presented at the ASCO Annual Meeting in June 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top